Method of treating suppurative septic complications of prostate adenoma

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, and may be used for treating suppurative septic complications of prostate adenoma. For this purpose, with underlying administering antibiotics, ozonised saline solution in the concentration of 3 to 6 mg/l in the amount of 200 to 400 ml is additionally intravenously administered; the therapeutic course is 3-5 injections depending on the patient's state. Besides, ozonised saline solution in the concentration of 5 to 8 mg/l is injected into the bladder in the preoperative preparation period, and from the second postoperative day, saline solution is introduced drop-by-drop in the amount of 400.0 ml daily five times with a two-way flushing system.

EFFECT: method enables reducing the risk of urosepsis, eliminating intoxication and accelerating postoperative wound healing of a BPH bed by anti-inflammatory, detoxification, analgesic action, improved blood rheology and microcirculation, increased local immunity with activated regenerative and reparative processes.

2 tbl, 1 ex

 

The invention relates to medicine, namely to urology.

Analogs of the invention

Known methods of treatment of inflammatory complications urinary tract antibacterial drugs and chemotherapy. Adenoma of the prostate in the examined patients, usually accompanied by chronic urinary retention and, as a consequence, chronic inflammatory changes. This condition occurs long, gradually leads to the narrowing of the prostatic urethra, persistent urinary tract infections and urosepsis.

The prototype inventions

As a prototype we have used the method described in the article VAZ et al., "Efficacy of fluoroquinolones in action on biofilm pathogens of urinary tract infections", published in the journal "Urology" (No. 1. str-16. 2010). This method is the use of norfloksatsina, levofloxacin and ofloxacin in the treatment of urinary tract infections.

Criticism prototype

Known methods of treatment using only antibacterial agents do not provide adequate clinical effect in the treatment of purulent-septic complications. Due to the accelerated destruction of microbial cells is the release of endotoxins, the degree of intoxication increases the likelihood urosepsis increases.

The purpose of the invention

The aim of the invention is the removal of purulent inflammatory process in machevo the bladder, purulent-septic conditions in the preoperative period and acceleration of postoperative wound surface healing Lodge of BPH.

The essence of the method consists in the following.

To achieve this goal intravenously injecting ozonated physiological solution. The ozonized physiological solution significantly improves microcirculation in inflammatory lesion increases the local immune status. To do this, use the system ozonation saline solution by the proposed method. Intravenous injection of ozonized physiological solution is performed by puncture of peripheral veins. With inadequate vascular access perform catheterization of the subclavian vein. For the introduction of ozonized physiological solution was used the standard system for intravenous infusion. The rate of infusion was 1 drop per second. All patients were performed from 3 to 5 intravenous infusions of ozonated saline solution, depending on the condition of the patient, not more than 3 times a week. Ozonated saline solution can be injected into the bladder in the preoperative preparatory period and from the second day after the operation using the two-way flushing system installed on the "float" in the course of operations, drip on 400,0 mldo 5 times daily.

The ozonized physiological solution produced at the facility WATA-60-01 " Madison" (Moscow). Certification test report No. 62-70 from 27.03.1998, the test centre medical products VNIIEM it №ROSS RU 000121 IMON, registration certificate No. 327/0753/97.

The initial ozone concentration ranged from 0.8 to 5 mg/l (average therapeutic concentration was 3.2 mg/l) for intravenous doing, for washing the bladder from 5 to 8 mg/l (average therapeutic concentration was 6.8 mg/l), in the amount of 200 to 400 ml. When the work was used dehiwala system - one needle was applied ozone-oxygen gas mixture, the second excess ozone, hovering above solution was applied to the destructor included in the device. For barbotirovaniya (saturation) was used only standard physiological solution of sodium chloride 0,89% - 200-400 ml prepared centrally. The ozone was supplied exclusively high-purity medical oxygen. The oxygen flow was 0.3-0.4 ml / min, the concentration of ozone in the gas phase - 55-60 mg/l ozonation time 15 to 30 - 45 seconds.

To standardize indicators of ozone concentration in the solution used the calibration according to the method provided by the software of the device. After that was done the calculation of the dose of ozone. The procedure is panels in terms of urology, office for ozone regime disinfection and kvartsevanie. With the circadian metabolism ozonation were mainly held in the first half of the day. Comparative characteristics of the blood picture of the two groups of patients are presented in table 1 and 2.

The example was made of the way.

The patient Aliyev Alia, 86 years old was admitted to the hospital 3.11.10. diagnosed with prostate Adenoma III epitestosterone, stone bladder exacerbation of chronic cystitis"On the preoperative period and after surgery in the treatment was conducted introduction of ozonized physiological solution as parenteral in a concentration of 2-4 mg/l, and through epitestosterone 7 mg/l within ten days. The degree of intoxication of plasma and erythrocytes before and after treatment is significantly lower than in other patients, the treatment of which was only used antibacterial agents. The patient was discharged in a short time after surgery, independent urination restored.

Comparative analysis of the characteristics of the prototype and the present invention

1. In the proposed method given a particular treatment of inflammatory diseases of the bladder and the bed adenomas using a certain concentration of ozonized physiological solution obtained by ozonation ozone-oxygen mixture with simultaneous determi is a bookmark accurate ozone concentration automatically. Detoxification property of ozone reduces the amount of endotoxin, respectively, reducing the degree of intoxication.

2. The prototype for the treatment of patients with inflammatory diseases and BPH use antibacterial fluoroquinolone series. Antibiotics as antimicrobial drugs, due to the destruction of microbial cells contribute to the release of endotoxins, the degree of intoxication increases.

The positive effect from the use of inventions

Clinical effect of ozone therapy is manifested anti-inflammatory and detoxifying effect, activating the immune system, improves rheology and microcirculation of the blood, and well corrigida gipoksemicescuu state, optimized Pro - and antioxidant system.

When local treatment of the wound surface ozone has anti-inflammatory and analgesic action. In high concentrations it has a direct antibacterial, antiviral, antifungal activity and able to stop the bleeding. At low concentrations of ozone activates the regenerative and reparative processes.

When ozone a potentiation of the effects of other drugs. For example, the combined application of ozone therapy and antibiotics, the dose of the latter can be reduced by 2-3 times. Ozone dose of 3-5 mg intravenously and 6-8 mg topically has efferent properties, resulting in reduced leukocyte index of intoxication in plasma and decreased erythrocyte sedimentation rate. The above positive qualities ozonirovannogo saline solution is recommended for inclusion in the complex treatment of patients suffering from BPH.

Table 1
Comparative evaluation of common blood and urine of patients with BPH depending on the way the pre-training
The group of patientsWithout the introduction of the ozoneWith the introduction of the ozoneχ2, df.P
Indicators on/analysis of blood and urineBefore treatment (M±m)After treatment (M±m)Before treatment (M±m)After treatment (M±m)
Hemoglobin (g/l)124±4125±3114±5133±4 χ258,1 p<0.06
ESR (mm/h)138±229±342±419±2χ219.2 p<0.002
The number of blood leukocytes χ10910.5±29.5±312.3±25.2±3χ25.03 p<0.05
The number of red blood cells χ10123.5±13.5±13.7±24.6±1χ21.9 p>0.005
Specific gravity of urine1010±51012±21007±31025±4χ25.02 p<0.04
Protein in the urine (ng/l)1.2±10.127±01.3±00.033±0χ21.6 p>0.003
Leukocytes in urine (p/SP)60±839±570±9 4±3χ229.3 p<0.003
The red blood cells in the urine (p/SP)30±719±442±52±1χ218.3 p<0.002
Bacteria in the urine (+)+++++++++++++χ21.8 p>0.04

Table 2
Comparative characteristics of biochemical parameters of blood in patients with BPH depending on the way the pre-training
The group of patientsWithout the introduction of the ozoneWith the introduction of the ozoneχ2, df.P
Biochemical parametersBefore treatment (M±m)After treatment (M±m)Before treatment (M±m)After treatment (M±m)
Urea (mmol/l)12,1 is 3 8,3±215,3±34,2±39,3 (p<0,02)
Creatinine (µmol/l)137,7±14to 133.5±6163,2±4124,3±58.9 (p<0.001)
Total bilirubin (mmol/l)16,7±517,2±219,3±29,3±310.5 (p<0.002)
Glucose (mmol/l)6,7±25,9±111,3±34,3±21.9 (p>0.005)

The method of treatment of purulent-septic complications in adenoma of the prostate by injection of antibiotics, characterized in that the patients additionally administered intravenously ozonized physiological solution at a concentration of from 3 to 6 mg/l in volume from 200 to 400 ml, the rate of 3-5 injections depending on the condition of the patient, in addition, the ozonized physiological solution at a concentration of from 5 to 8 mg/l is injected into the bladder in the preoperative preparatory period and from the second day after surgery drip on 400,0 ml e is dnevno 5 times using the two-way flushing system.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (1), in which Ar is a group of formula (Ar-1) or (Ar-2), in which R1 is a halogen, R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, alkyl or alkenyl, X is a nitrogen atom or CH, R5 and R6 are each hydrogen and h equals 1; 1 equals 1 or 2; m equals 1 or 2; n equals 0, 1 or 2; o equals an integer from 0 to 3, under the condition that n and o are equal to 0 at the same time. Values of group A are as given in claim 1 of the invention. Described also is a pharmaceutical composition having agonistic activity with respect to 7 serotonin (5-HT4-receptors), which contains a compound of formula (1) and an agent which stimulates enterokinesis or improves functioning of the alimentary canal, which contains a compound of formula (1) as an active ingredient.

EFFECT: novel compounds are obtained and described, which have strong affinity towards 4 serotonin receptors, which are useful as an agent which stimulates enterokinesis or an agent which improves functioning of the alimentary canal.

28 cl, 233 ex, 29 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology, and can be used for treatment of chronic abacterial prostatitis in men, which is not connected with dysfunction of urethral sphincter. For this purpose, efficient amount of fispemiphene is introduced to patient who needs it. Introduction of fispemiphene is performed in amount in the range from 0.1 to approximately 100 mg/kg of body weight.

EFFECT: invention ensures efficient treatment of abacterial prostatitis at the early stage of disease where only histological changes of prostate gland are present without presence of urethral sphincter dysfunction, with drug fispemiphene, which demonstrates antagonistic activity to estrogen receptors in particular with respect to prostate tissue.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutical industry, in particular to composition, which contains epigallocatechine-3-gallate as active component and target additive. Pharmaceutical composition for peroral introduction, which contains epigallocatechine-3-gallate and block-copolymer of oxyethylene and oxypropylene, in which content of hydrophobic block constitutes not less than 50 wt %, and molecular weight of hydrophilic block constitutes 2250 Dalton and not more, with specified weight ratio of epigallocatechine-3-gallate and block copolymer 1:1-10:1. Application of upper described pharmaceutical composition for treatment of atopic dermatitis, Crohn's disease, adenomyosis, and hyperplastic diseases of prostate.

EFFECT: composition has increased bioavailability in peroral application, improves absorption of active compound epigallocatechine-3-gallate in blood flow.

6 cl, 2 dwg, 4 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely technology of preparation of rectal suppositories. The suppositories with solid licorice extract consist of solid licorice extract 0.75 g on a hydrophilic base, polyethylene glycol 6000 1.25 g and polyethylene glycol polystear 0.25 g.

EFFECT: making the preparations exhibiting anti-inflammatory action, and also a positive effect on the hormonal status and the copulative function.

7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) which is selected from gentisate, maleate, citrate, fumarate and semitartrate salts, which possess improved properties in their application, in particular higher stability.

EFFECT: invention also relates to method of obtaining acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) and to pharmaceutical composition, containing them, for treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive lung disease, benign prostate gland hypertrophy and diseases of lower urinary tract.

11 cl, 30 ex, 7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions relates to medicine. There are declared methods of treatment and preventive treatment of prostate cancer in males and a method for treatment of prostate cancer in male dogs involving a single agent therapy in the form of introducing a therapeutic amount of N,N'-bis(2,3-butadienyl)-1,4-butane-diamine or its pharmaceutically acceptable salt or solvate. The therapeutic amount is specified within the range from 1-100 mg/kgbody weight and dosed within the range from twice a week to once a day.

EFFECT: group of inventions has high therapeutic efficacy.

26 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to coated pharmaceutical formulations with a controlled-release active substance and to the use thereof for treating benign prostatic hyperplasia. The formulation contains a therapeutically effective amount of the active substance representing tamsulosin or its pharmaceutically acceptable salt encapsulated in a granulated core, and an insoluble permeable polymer found both in the granulated core and in the coating. Said pharmaceutical formulations may also contain a surfactant and other optional excipients. Besides, the invention refers to a method for preparing the pharmaceutical formulations which involves mixing core ingredients, granulating, pressing and shaping in a sphere, drying and coating.

EFFECT: invention provides the formulations with pH-independent release of the active substance, low inter-individual variability and low biological variability.

14 cl, 7 ex

FIELD: medicine.

SUBSTANCE: The invention relates to pharmacology, in particular, to medication for preventing or treating herpes labialis or herpes genitalis. The homeopathic medication or biologically active additive with anti-viral effect or preventing or treating herpes labialis or herpes genitalis contains: Nisylen, Cepa, Euphrasia, Belladonna and Mericulis Solubilis, furthermore, the components are present with a certain dilution and amount. The combination of the said components is used for production of homeopathic medication or biologically active additive with anti-viral effect or preventing or treating herpes labialis or herpes genitalis.

EFFECT: production of medication which effectively treats herpes labialis or herpes genitalis.

14 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers namely to pharmaceutical industry, and concerns tablets with the slowed down liberation, containing alfuzosin hydrochloride. The tablet includes: the top layer including 0,2 weight parts of alfuzosin HC1, 90 weight. parts of hypromellose, 29. 6 weight parts of polyethylene oxide, 1 weight part of stearyl alcohol, 0.4 weight parts of easy waterless silicon acid and 1 weight part of ethyl cellulose; and the bottom layer including 9.8 weight parts alfuzosin HC1, 36-62 weight parts of microcrystalline cellulose, 24-60 weight parts of polyethylene oxide, 20 weight parts low substituted hydroxypropyl cellulose, 1-6 weight parts of stearyl alcohol and 99 weights parts of hydroxypropyl cellulose.

EFFECT: received tablet is characterized by the liberation of the medicine with the curve of the zero order.

3 cl, 2 tbl, 10 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: invention is referred to the area of medicine. The remedy for treatment of kidney stone disease of urogenital system is the bile of poultry and game. The bile of healthy poultry or game can be using for treatment in any form, including raw fresh bile, solution containing certain dose of the bile, as a composition, containing food product, for example, honey, and raw fresh bile as a powder dissolved in the water, as tablets or capsules.

EFFECT: The invention will allow to increased number of products of non-chemical natural origin having increasing effectiveness for the treatment of kidney stone disease.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to traumatology, oncology, pulmonology and surgery, and can be applied for treatment of pleurisy. For this purpose immediately after removal of exudate from pleural cavity into it introduced is wide-spectrum antibiotic and intravenously introduced is amikacin, after 10 minutes patient does 5 forced inhalations and exhalations with 3-minute intervals. After 10 minutes chest is subjected to electrophoresis with potassium iodide solution, which after day is alternated with solution of calcium chloride, with anode being placed into the space between scapular and midaxillary line at the level of 4-th rib to lower edge of rib arc. After finishing each session strips of capsicum plaster are stuck on back around shoulder-blades from both sides for one day, not less than 3 times.

EFFECT: method makes it possible to improve results of treatment and reduce development of complications by fast arrest of disease with adequate anti-inflammatory therapy and sanitisation of pleural cavity.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, and can be used in surgical treatment of patients with multilocular echonococcosis of liver. For this purpose transcutaneous drainage of cyst with further aspiration of its content is performed. After that, scolicide preparation is introduced. As scolicide preparation with 3-minute exposure 1% introduced is water solution of sodium hypochlorite in volume equal 1/3 of volume of aspirated liquid. After that, cyst content is re-aspirated. Procedure is repeated until "pure" aspirated liquid is obtained three times.

EFFECT: method makes it possible to ensure adequate and least traumatic treatment of said pathology without application of X-ray control due to application of definite sequence of techniques, as well as use of scolicide preparation, destroying envelopes of daughter echinococcal cysts.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to neurosurgery and traumatology. During surgery, which is realised from front access, installation of two catheters into epidural space is performed. Installation of catheters is performed by means of needles through separate punctures. Punctures are made with 2-3 cm indent from lateral edge of operation wound. Catheters are installed onto dura mater of spinal cord under and above its injury, orienting them in caudal and cranial directions. After that, operation wound is sutured. In post-operative period perfusion of spinal cord with 0.9% of sodium chloride solution, cooled to temperature +5÷8°C, is performed by means of installed catheters at rate 40-60 drop/min until temperature of solution, flowing out of epidural space, reaches +9÷11°.

EFFECT: method makes it possible to reduce risk of development of post-operative complications.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to vascular surgery and anesthesiology, and can be applied in surgical treatment of varicose disease of lower extremities with application of endovasal laser coagulation of veins. For this purpose paravasal infiltration of tumescent solution is realised. As such, cooled to 6-7C0 ozonised 4-5 mkg/l physiological solution is introduced. Introduction is carried out under continuous ultrasonic navigation into fascial sheath of coagulating vessel and hypodermic cellular tissue.

EFFECT: method makes it possible to ensure reduction of expression of post-operative pain syndrome, as well as prevent development of local inflammatory complications due to vein spasm and neutralisation of warming up of cellular-tissue structures at the moment to laser exposure.

Nootropic agent // 2475250

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an agent exhibiting nootropic action. The declared agent contains calcium chloride, sodium chloride, ferric sulphate (II), zinc sulphate, chromium chloride (III) and potassium bromide in certain proportions.

EFFECT: invention provides normalisation of the CNS function ensured by nootropic action.

1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at prevention of complications following the intestinal operations, at prevention of intestinal anastomotic leak, ischemic disorders in enteroenteroanastomosis in periotonitis, acute intestinal obstruction. There are involved the intra- and immediate postoperative introductions of hydroxyethyl starch (HES) 130/0.4 and balanced polyionic crystalloid solutions in ratio 1:3. The volume is gradually reduced to achieve the volume 3 times less than the initial one by the 7th day.

EFFECT: method enables reducing a probability of postoperative intestinal anastomotic leak.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely surgery, and may be used for treating patients with trophic ulcers. That is ensured by the sequential intravenous drop-by-drop introduction of a mixture containing 5% glucose 200 ml, 0.5% Novocaine 50 ml, 25% magnesium sulphate 5 ml; that is followed by the introduction of a mixture containing 0.9% normal saline 200 ml, 2% pentoxifylline 5 ml and the introduction of a mixture containing rheopolyglucin 200 ml, 5% ascorbic acid 5 ml, 1% nicotinic acid 1 ml.

EFFECT: method enables stimulating trophic wound healing ensured by improved microcirculation and clinical course of metabolic processes.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely obstetrics and gynaecology, and may be used for relieving blood loss in managing non-developing pregnancy. That is ensured by intravenous drop-by-drop introduction of tranexamic acid 0.75 g dissolved in 0.9% sodium chloride 200 ml for 20-30 minutes in the first trimester of a gestation perion 30-60 minutes before instrumental extraction of a dead embryo from an uterine cavity.

EFFECT: method provides relieving blood loss and prevented developing coagulopathic bleeding.

3 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely neurosurgery, and may be used for treating patients with complicated cervical spine injury. That is ensured by surgical intervention by spinal cord decompression, stabilization of the injured spinal motion segments, catheterisation of the epidural space and local hypothermia of the spinal cord. The local hypothermia of the spinal cord is performed by sodium chloride cooled to +5°C. To improve metabolic processes of nerve tissue and to avoid pyoinflammatory complications, a standard drug-induced therapy is prescribed from the first postoperative day. On the each 7th postoperative day, blood serum is examined by ELISA for matrix metalloproteinase MMP-2 and MMP-9, anti-neuronal immunoglobulin anti-MAG, phosphorylated neurofilament pNP-H, myelin basic protein MBP, tissue inhibitor of metalloproteinase TIMP-1 count. It is followed by calculating nerve tissue damage and nerve tissue restoration ratios by specific formulas. The derived values are estimated. Their total value is used to specify the following therapeutic approach. If the value is negative, the local hypothermia of the spinal cord is continued. If the value is positive, the local hypothermia is terminated; the catheters are removed; electrodes are punctured through interspinous spaces into the epidural space below and above the injured segments, and the spinal cord is electrically stimulated.

EFFECT: method provides higher clinical effectiveness, reduced risk of postoperative complications, earlier starting date of rehabilitation measures ensured by choosing an individual therapeutic approach.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to pharmacology and medicine, in particular, to gastroenterology, and represents medication for intestinal lavage, which includes sodium chloride, potassium chloride, sodium phosphate disubstituted, citric acid, sodium acetate, magnesium sulphate and boiled water, characterised by the fact that it additionally contains sorbite, with medication components being in specified ratio.

EFFECT: invention ensures achievement of comfortable, predicted complete emptying of intestine, which does not cause unpleasant sensations and impairment of electrolytic composition of blood and tissues.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and represents a method of 14-day individual's health improvement involving depletion, clay therapy, sauna procedures, physiologically separate food, patient's electronic testing for the parameters of the primary life-support systems, and comparing of the test results with satisfactory normal results; the comparative analysis aims at determining the optimal health improvement regimens consisting in depletion, separate food, sauna procedures, lung purification and dilatation, blood oxygen increase by breathing exercises, auditory memory promotion and prescribed parasiticide preparations, Hatha Yoga gymnastics, intestinal massage on the seventh, ninth, twelfth days.

EFFECT: invention enhances the silicone digestibility and increases its content, restores the gastrointestinal microflora, toxin and waste body purification, anthelminthic treatment, musculoskeletal recovery, improved psychological state, memory and respiratory system.

3 ex

Up!